Cover Image
市場調查報告書

念珠菌感染:開發平台分析

Candidiasis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192515
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
念珠菌感染:開發平台分析 Candidiasis - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 151 Pages
簡介

念珠菌感染主要是感染白色念珠球菌這種念珠菌而引起。皮膚的念珠球菌感染症特徵為清楚的出現紅斑、皮膚癢、許多情況下還會有體液滲出。也常見有瘡痂、膿皰。常見於鼠蹊部·臀部內側等、胸部中間、腳趾間、手指間、臍帶等也很常見。治療方法包含抗真菌藥物等。

本報告提供念珠菌感染的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

念珠菌感染概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

正在開發的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Amplyx Pharmaceuticals, Inc.
  • Bakker Medical Srl
  • Biomar Microbial Technologies
  • Cellceutix Corporation
  • Cidara Therapeutics, Inc.
  • Daewoong Pharmaceutical Co., Ltd.
  • General Biologicals Corporation
  • Grupo Ferrer Internacional, S.A.
  • Hsiri Therapeutics, LLC
  • Nanomerics Ltd
  • Novabiotics Limited
  • NovaDigm Therapeutics, Inc.
  • Onxeo SA
  • Panacela Labs, Inc.
  • Scynexis, Inc.
  • Sealife PHARMA GMBH
  • TGV-Laboratories
  • Viamet Pharmaceuticals, Inc.
  • Wellstat Vaccines, LLC

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 61894700
  • AC-17
  • amphotericin b
  • amphotericin B
  • amphotericin B
  • APX-001
  • arasertaconazole
  • Candida vaccine
  • candidiasis vaccine
  • CD-101
  • CTIX-1502
  • DWP-06081
  • Forazoline A
  • KSL-W
  • MH-010
  • miconazole nitrate
  • Monoclonal Antibodies to Target Fba for Candidiasis
  • mutanobactins
  • Myc-102
  • NDV-3
  • NDV-3A
  • NP-339
  • obliquumol
  • PAC-113
  • pegylated amphotericin B
  • PMX-1408
  • PMX-1570
  • PMX-1576
  • PMX-1591
  • PMX-1625
  • PMX-519
  • PMX-70004
  • Prof-002
  • Recombinant Peptides for Oropharyngeal Candidiasis
  • SCY-078
  • SLP-0901
  • SLP-0904
  • Small Molecule for Bacterial Vaginosis and Candidiasis
  • Small Molecule for Fungal Infections
  • Small Molecule for Systemic Candidiasis
  • Small Molecules for Aspergillosis and Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Candidiasis
  • Small Molecules for Fungal Infections
  • Small Molecules for Fungal Infections
  • Synthetic Peptide for Multi-Drug Resistant Microbial Infections
  • VT-1161
  • XELRYX-3

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8343IDB

Summary

Global Markets Direct's, 'Candidiasis - Pipeline Review, H2 2016', provides an overview of the Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Candidiasis
  • The report reviews pipeline therapeutics for Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Candidiasis therapeutics and enlists all their major and minor projects
  • The report assesses Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Candidiasis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Candidiasis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Candidiasis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Candidiasis Overview
  • Therapeutics Development
    • Pipeline Products for Candidiasis - Overview
    • Pipeline Products for Candidiasis - Comparative Analysis
  • Candidiasis - Therapeutics under Development by Companies
  • Candidiasis - Therapeutics under Investigation by Universities/Institutes
  • Candidiasis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Candidiasis - Products under Development by Companies
  • Candidiasis - Products under Investigation by Universities/Institutes
  • Candidiasis - Companies Involved in Therapeutics Development
    • Amplyx Pharmaceuticals, Inc.
    • Bakker Medical Srl
    • Biomar Microbial Technologies
    • Biosergen AS
    • Cellceutix Corporation
    • Cidara Therapeutics, Inc.
    • Daewoong Pharmaceutical Co., Ltd.
    • Dermala Inc
    • General Biologicals Corporation
    • Grupo Ferrer Internacional, S.A.
    • Hsiri Therapeutics, LLC
    • iCo Therapeutics Inc.
    • Matinas BioPharma Holdings, Inc.
    • Nanomerics Ltd
    • Novabiotics Limited
    • NovaDigm Therapeutics, Inc.
    • Onxeo SA
    • Scynexis, Inc.
    • Sealife PHARMA GMBH
    • TGV-Laboratories
    • Viamet Pharmaceuticals, Inc.
    • Wellstat Vaccines, LLC
  • Candidiasis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (clotrimazole + diclofenac sodium) - Drug Profile
    • (clotrimazole + diclofenac sodium) 1 - Drug Profile
    • 61894700 - Drug Profile
    • AC-17 - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • amphotericin B - Drug Profile
    • Antibody to Target Ece1 for Candidiasis - Drug Profile
    • APX-001 - Drug Profile
    • arasertaconazole - Drug Profile
    • BSG-005 - Drug Profile
    • candidiasis vaccine - Drug Profile
    • CD-101 - Drug Profile
    • Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
    • CTIX-1502 - Drug Profile
    • Drug for Candidiasis - Drug Profile
    • DWP-06081 - Drug Profile
    • Forazoline A - Drug Profile
    • iCo-010 - Drug Profile
    • KSL-W - Drug Profile
    • MH-010 - Drug Profile
    • miconazole nitrate - Drug Profile
    • Monoclonal Antibodies for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis - Drug Profile
    • Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
    • Monoclonal Antibody to Inhibit the Beta-Glucan for Fungal Infections - Drug Profile
    • mutanobactins - Drug Profile
    • Myc-102 - Drug Profile
    • NDV-3 - Drug Profile
    • NDV-3A - Drug Profile
    • NP-339 - Drug Profile
    • obliquumol - Drug Profile
    • Occidiofungin - Drug Profile
    • PAC-113 - Drug Profile
    • PMX-1408 - Drug Profile
    • PMX-1570 - Drug Profile
    • PMX-1576 - Drug Profile
    • PMX-1591 - Drug Profile
    • PMX-1625 - Drug Profile
    • PMX-519 - Drug Profile
    • PMX-70004 - Drug Profile
    • Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
    • SCY-078 - Drug Profile
    • SLP-0901 - Drug Profile
    • SLP-0904 - Drug Profile
    • Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
    • Small Molecule for Fungal Infections - Drug Profile
    • Small Molecules for Aspergillosis and Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Candidiasis - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Fungal Infections - Drug Profile
    • Small Molecules for Systemic Candidiasis - Drug Profile
    • Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
    • Synthetic Peptides for Candidiasis - Drug Profile
    • Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
    • TOL-463 - Drug Profile
    • Vaccine for Fungal Infections - Drug Profile
    • Vaccine to Target Ece1 for Candidiasis - Drug Profile
    • VT-1161 - Drug Profile
  • Candidiasis - Dormant Projects
  • Candidiasis - Discontinued Products
  • Candidiasis - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Candidiasis, H2 2016
  • Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Candidiasis - Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016
  • Candidiasis - Pipeline by Bakker Medical Srl, H2 2016
  • Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2016
  • Candidiasis - Pipeline by Biosergen AS, H2 2016
  • Candidiasis - Pipeline by Cellceutix Corporation, H2 2016
  • Candidiasis - Pipeline by Cidara Therapeutics, Inc., H2 2016
  • Candidiasis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
  • Candidiasis - Pipeline by Dermala Inc, H2 2016
  • Candidiasis - Pipeline by General Biologicals Corporation, H2 2016
  • Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H2 2016
  • Candidiasis - Pipeline by Hsiri Therapeutics, LLC, H2 2016
  • Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2016
  • Candidiasis - Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016
  • Candidiasis - Pipeline by Nanomerics Ltd, H2 2016
  • Candidiasis - Pipeline by Novabiotics Limited, H2 2016
  • Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H2 2016
  • Candidiasis - Pipeline by Onxeo SA, H2 2016
  • Candidiasis - Pipeline by Scynexis, Inc., H2 2016
  • Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2016
  • Candidiasis - Pipeline by TGV-Laboratories, H2 2016
  • Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H2 2016
  • Candidiasis - Pipeline by Wellstat Vaccines, LLC, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Candidiasis - Dormant Projects, H2 2016
  • Candidiasis - Dormant Projects (Contd..1), H2 2016
  • Candidiasis - Dormant Projects (Contd..2), H2 2016
  • Candidiasis - Dormant Projects (Contd..3), H2 2016
  • Candidiasis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Candidiasis, H2 2016
  • Number of Products under Development for Candidiasis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top